Medical testing company regulatory filing citing a Nature Medicine paper — Caredx, 2024-07-31
CaredxCaredxNASDAQ CDNA
Filings SEC · Quote Yahoo cited a paper published in Nature MedicineNature Medicine
Journal · Website as the basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange CommissionU.S. Securities and Exchange Commission
Regulator · Website. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. The stock price movement for one month after the filing was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.
The disclosure wrote the paper in the press release like this
When a U.S. listed company has something to inform shareholders, the unscheduled report it files with the Securities and Exchange Commission is called 8-K. The item number of the document filed by Caredx on 2024-07-31 was 2.02 Earnings announcement · 9.01 Financial statements · Attached documents. The company cited a paper published in Nature Medicine in the press release attached to it. Translating the sentence in the original document that cites the paper verbatim, it reads as follows.
Cell-Free DNA for the detection of kidney allograft rejection.
What readers should look at first is where the company placed the paper in the press release. Next, they should determine whether the paper supports the entire company's claim or only a part of it. To answer the latter question, one must read the full paper. This article, which reads only the abstract, cannot answer that.
The scope of the paper mentioned in the abstract is limited to this
The title of the paper is Cell-free DNA for the detection of kidney allograft rejection and it was published in Nature Medicine on 2024-06-02. The authors' affiliations are Inserm · Université Paris Cité · Assistance Publique – Hôpitaux de Paris · KU Leuven. The summary published at the beginning of the paper is called abstract. This article read only up to there. This paragraph was rewritten by a person after filtering a draft written by a machine reading the abstract by numerical comparison, so it is a different grade from a full-text reading and a verified reading.
An observational study collected data from 2,882 kidney transplant recipients across 14 transplant centers in Europe and the United States to evaluate how well donor-derived DNA fragments in the blood detect rejection. These DNA levels were strongly associated with antibody-mediated, T-cell-mediated, and mixed-type rejection. Even when combined with existing test parameters, the signal remained independent. Adding this metric to existing models for calculating rejection risk improved the discrimination ability from 0.777 to 0.821, and the same result was observed in a separate validation group of 1,748 individuals. Since this is an observational study, the paper does not address whether using this test to manage patients improves outcomes.
What the abstract does not answer remains in the full text and appendices. This article leaves gaps as gaps. Readers must compare the two citations above to determine which sentence in the abstract corresponds to the company's cited excerpt.
One month later, the stock price was within the top quarter of the sample.
The remaining return after subtracting the portion attributable to market movement is called excess return. Dates are counted only on days when the stock market is open, referred to as trading days. In calendar terms, 20 trading days is approximately one month. The excess return on the day of the regulatory filing and for the following month are listed in the table below.
| Period | Excess return relative to the market | Meaning |
|---|---|---|
| Five trading days before the filing | −0.7% | The extent of movement before the filing |
| On the filing date | +6.0% | On the filing date or the first trading day thereafter |
| Cumulative over +1 to +5 trading days | +35.6% | One week |
| Cumulative over +1 to +20 trading days | +47.6% | One month |
A bundle of past cases of the same type is called a sample. The position counted from the bottom is expressed as a percentile. The one-month excess return of +47.6% in this case is within the top quarter, corresponding to the 97% position from the bottom among 142 samples.
| Sample scale (20 trading days) | Tenth from the bottom | Fourth from the bottom | Median | Top 25% | Top 10% | This case |
|---|---|---|---|---|---|---|
| Excess return | −31.9% | −20.1% | −7.4% | +5.5% | +18.7% | +47.6% |
Half of the sample falls between the two central marks on the chart. One checks the chart to see whether this case lies within or outside the range. The sample collects cases where U.S.-listed companies cited papers in 8-K filings over the past decade. The company itself is excluded from the sample. The numbers listed here are past facts, not rules applicable to future cases.
After the filing, the company issued such documents.
Three 8-K filings issued by the company after the filing date are listed by item number only. In 8-K filings without titles, the item number indicates the type of content. Whether it was an earnings announcement or a contract can be identified by the number. The details of what occurred are read in the original text via each link.
- 2024-09-12 8-K Items 5.02,8.01,9.01 — Officer/Director Changes · Other Events · Financial Statements and Exhibits
- 2024-10-04 8-K Items 5.02,9.01 — Officer/Director Changes · Financial Statements and Exhibits
- 2024-10-08 8-K Item 8.01 — Other Events
What this article does not answer
This article, based only on abstracts, cannot answer what methods the paper used, what it reviewed, or what it demonstrated. How many times the cited paper was referenced afterward can be verified again using the citation count from OpenAlexOpenAlex
Data source · Website. What will be examined next is whether the company's subsequent 8-K filing cites the same paper again.
Glossary
- 8-K
- A voluntary report submitted to the Securities and Exchange Commission when a U.S. listed company has something to inform shareholders. Types are indicated by item numbers such as earnings, contracts, and executive changes. All events in this article come from this document.
- Excess return
- The remainder after subtracting the overall market return from the stock return. It is used to see the movement of the company alone by removing the portion where the market as a whole rises or falls.
- Trading day
- A date counting only the days the stock market is open. Since weekends and holidays are excluded, 20 trading days are about a month in the calendar.
- Sample and percentile
- A bundle of past cases of the same type is a sample, and the position from the bottom is expressed as a percentile. A percentile of 10 means that nine out of ten cases performed better than this case.
- Abstract
- A summary placed at the beginning of a paper. The author writes in a few sentences what was done, how it was done, and what results were obtained. Without reading the full text, one cannot know the details and limitations of the method.